Abstract:The prevalence of psychiatric disorders has increased in recent years. Among existing mental disorders, major depressive disorder (MDD) has emerged as one of the leading causes of disability worldwide, affecting individuals throughout their lives. Currently, MDD affects 15% of adults in the Americas. Over the past 50 years, pharmacotherapy, psychotherapy, and brain stimulation have been used to treat MDD. The most common approach is still pharmacotherapy; however, studies show that about 40% of patients are refractory to existing treatments. Although the monoamine hypothesis has been widely accepted as a molecular mechanism to explain the etiology of depression, its relationship with other biochemical phenomena remains only partially understood. This is the case of the link between MDD and inflammation, mitochondrial dysfunction, and oxidative stress. Studies have found that depressive patients usually exhibit altered inflammatory markers, mitochondrial membrane depolarization, oxidized mitochondrial DNA, and thus high levels of both central and peripheral reactive oxygen species (ROS). The effect of antidepressants on these events remains unclear. Nevertheless, the effects of ROS on the brain are well known, including lipid peroxidation of neuronal membranes, accumulation of peroxidation products in neurons, protein and DNA damage, reduced antioxidant defenses, apoptosis induction, and neuroinflammation. Antioxidants such as ascorbic acid, tocopherols, and coenzyme Q have shown promise in some depressive patients, but without consensus on their efficacy. Hence, this paper provides a review of MDD and its association with inflammation, mitochondrial dysfunction, and oxidative stress and is aimed at thoroughly discussing the putative links between these events, which may contribute to the design and development of new therapeutic approaches for patients.

Use of Extracellular Monomeric Ubiquitin as a Therapeutic Option for Major Depressive Disorder

The roles of extracellular vesicles in major depressive disorder

New and emerging treatments for major depressive disorder

Nutrition, Epigenetics, and Major Depressive Disorder: Understanding the Connection

Major depressive disorder as a neuro-immune disorder: Origin, mechanisms, and therapeutic opportunities

Targeting Inflammatory-Mitochondrial Response in Major Depression: Current Evidence and Further Challenges

Exploring the role of inflammation in major depressive disorder: beyond the monoamine hypothesis

Gut Microbiota Metabolites in Major Depressive Disorder—Deep Insights into Their Pathophysiological Role and Potential Translational Applications

An overview of major depression disorder: The endocannabinoid system as a potential target for therapy

Targeting the inflammatory pathway as a therapeutic tool for major depression.

Gut microbiota, innate immune pathways, and inflammatory control mechanisms in patients with major depressive disorder

Emerging drugs for the treatment of major depressive disorder

Increased expression of ER stress, inflammasome activation, and mitochondrial biogenesis-related genes in peripheral blood mononuclear cells in major depressive disorder

Targeting inflammation: a potential approach for the treatment of depression

Plasma Disturbance of Phospholipid Metabolism in Major Depressive Disorder by Integration of Proteomics and Metabolomics

[Update on Immune and Metabolic Dysregulation in Major Depressive Disorder and the Implications for Drug Intervention].

Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets

A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder

The role and advance of ubiquitination and deubiquitination in depression pathogenesis and treatment

Dysregulated Protein Synthesis in Major Depressive Disorder

From Early Diagnosis to Emerging Treatment Options